ArticleNature communications2024
Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.The Journal of pathology · 2026Article
- Excess cysteine drives conjugate formation and impairs proliferation of NRF2-activated cancer cells.Nature metabolism · 2026Article
- Reactive oxygen species in health and disease.Molecular biomedicine · 2026Review
- NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions.GeroScience · 2026Article
- Fluorinated Carnitine Derivatives as Tools to Visualise Carnitine Transport and Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Wise as a Serpent and Gentle as a Dove: Pharmacological Targeting of NRF2/KEAP1 Pathway from Treasure Trove of Mother Nature.Drug design, development and therapy · 2026Review
- Ferroptosis and cancer: when iron turns against tumors.Cellular and molecular life sciences : CMLS · 2025Review
- Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) as a Biomarker for Radiation Dosimetry and Health Risk Assessment: A Review.Antioxidants (Basel, Switzerland) · 2025Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- NRF2 activation in cancer and overview of NRF2 small molecule inhibitors.Archives of pharmacal research · 2025Review
- Ferroptosis and Metabolic Dysregulation: Emerging Chemical Targets in Cancer and Infection.Molecules (Basel, Switzerland) · 2025Review
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nature reviews. Clinical oncology · 2025Review
- Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies.Cancers · 2025Review
- Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.Redox biology · 2025Review
- Compact and cGMP-compliant automated synthesis of [EJNMMI radiopharmacy and chemistry · 2025Article
- A novel approach to enhance beta-sitosterol bioavailability isolated fromFrontiers in oncology · 2025Article
- The implication of aberrant NRF2 activation in management of female cancers.Frontiers in oncology · 2025Review
Corrections and comments
- Update of
Authors and funding
23 authors.
Hannah E GreenwoodSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Abigail R BarberSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.ORCID 0009-0008-0238-2686
Richard S EdwardsSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Will E TyrrellSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Madeleine E GeorgeSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Sofia N Dos SantosSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Friedrich BaarkSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Muhammet TancSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Eman KhalilSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Aimee FalzoneDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Nathan P WardDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0003-4920-0081
Janine M DeBlasiDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Laura TorrenteDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Pritin N SoniDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
David R PearceCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.ORCID 0000-0001-8443-2924
George FirthSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Lydia M SmithSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Oskar Vilhelmsson TimmermandSchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Ariana HuebnerCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.ORCID 0000-0001-8009-4999
Charles SwantonCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.ORCID 0000-0002-4299-3018
Robert E HyndsCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.ORCID 0000-0002-2170-8791
Gina M DeNicolaDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0001-6611-6696
Timothy H WitneySchool of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK. tim.witney@kcl.ac.uk.ORCID 0000-0002-9475-2873
Funding
Investigation of NRF2-Dependent Metabolic LiabilitiesR37CA230042 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI DENICOLA, GINA MARIE · 2018 to 2024
$2.8MNCI NIH HHS R37 CA230042Wellcome Trust CC2041Wellcome Trust (Wellcome) 220221/Z/20/ZWellcome Trust (Wellcome) WT209199/Z/17/Z
Abstract
Mutations in the NRF2-KEAP1 pathway are common in non-small cell lung cancer (NSCLC) and confer broad-spectrum therapeutic resistance, leading to poor outcomes. Currently, there is no means to non-invasively identify NRF2 activation in living subjects. Here, we show that positron emission tomography imaging with the system x
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsNF-E2-Related Factor 2Positron-Emission TomographyAnimalsCell Line, TumorFemaleFluorine RadioisotopesHumansKelch-Like ECH-Associated Protein 1MiceRadiopharmaceuticalsFluorine RadioisotopesKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2Radiopharmaceuticals
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.